Cannabinoid-based pharmaceuticals company Teewinot Life Sciences Corporation this morning announced that it has been granted U.S. Patent No. 9,861,609. Per the update, the newly-issued patent has broad claims to biosynthetic methods for the pharmaceutical manufacture of cannabinoids and cannabinoid analogs. “With the grant of the ‘609 patent, Teewinot has now secured six U.S. patents covering processes for the manufacture of naturally-occurring cannabinoids, cannabinoid prodrugs and analogs using both biocatalysis and synthetic biology,” Dr. Richard Peet, Teewinot’s executive vice president and co-inventor of the new patent, stated in the news release. “Teewinot has filed patent applications in key countries around the world. The ‘609 patent is an important addition to Teewinot’s valuable patent portfolio.” To date, the Teewinot Group is the only company with a U.S.-granted patent portfolio in the biosynthetic production of cannabinoids. Leveraging this advantage, the company is currently focused on rapidly moving cannabinoid-based agents into the clinic to provide novel patient therapies.
To view the full press release, visit http://nnw.fm/8aIQK
About Teewinot Life Sciences Corporation
Teewinot Life Sciences Corporation is an international cannabinoid biopharmaceutical company focused on advanced pharmaceutical research and product development. Teewinot’s novel platform manufacturing technology enables the production and delivery of products containing cannabinoids, cannabinoid prodrugs, and cannabinoid analogs. With headquarters in Tampa, Florida, and subsidiaries, Teewinot Technologies Ltd. in Ireland and Teewinot Laboratories, Inc. in Canada, The Teewinot Group’s revolutionary technologies and intellectual property portfolio represent a breakthrough in creating safe and standardized cannabinoids. For more information, visit the company’s website at www.TLSCorp.com
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
